Kluwer Patent Blog published a new post by Kirill Osipov July 29, 2025 The patent dispute relating to the cancer drug Tagrisso (osimertinib) and the role of the Federal Antimonopoly Service (FAS) of Russia as the main regulator of the case is the theme of the new post by Kirill Osipov, the Head of Legal Department at ARS-Patent. In cooperation with experts from the leading IP firms worldwide, Kluwer Patent Blog provides updates and developments in patent law, featuring in-depth analysis and insights from leading IP professionals. You can read the post on Kluwer Patent Blog via the link. Make an enquiry
MEET WITH US Meet ARS-Patent at the AIPPI World Congress 20262026-08-26The AIPPI World Congress 2026 will be held in Hamburg, Germany, from 7 to 10 October 2026, bringing together thousands of intellectual property profes...Read moreARS-Patent will attend the APAA 2025 in Kuala Lumpur2025-10-03We are pleased to announce that ARS-Patent will be a part of the upcoming global IP event APAA 2025, which is the 21st General Assembly and 77th & 78t...Read moreSee all Events
Meet ARS-Patent at the AIPPI World Congress 20262026-08-26The AIPPI World Congress 2026 will be held in Hamburg, Germany, from 7 to 10 October 2026, bringing together thousands of intellectual property profes...Read more
ARS-Patent will attend the APAA 2025 in Kuala Lumpur2025-10-03We are pleased to announce that ARS-Patent will be a part of the upcoming global IP event APAA 2025, which is the 21st General Assembly and 77th & 78t...Read more
